Karyopharm Therapeutics is a pharmaceutical company that develops and commercializes targeted therapies focusing on nuclear transport inhibition to treat patients with cancer and other major diseases.
Karyopharm Therapeutics ranks #26 on the 2026 Top 100 Global Most Loved Workplaces®, awarded by Best Practice Institute — recognized in the Biotechnology sector, headquartered in Newton, Massachusetts, United States.
Karyopharm Therapeutics is a pharmaceutical company that develops and commercializes targeted therapies focusing on nuclear transport inhibition to treat patients with cancer and other major diseases.
Best Practice Institute is the research organization behind Most Loved Workplace® certification, the SPARK Model, the Love of Workplace Index™ (LOWI™), and The Workplace Report.
The Workplace Report is BPI's original workplace culture research and editorial briefing series for CEOs, CHROs, people leaders, talent leaders, and employer-brand teams. It turns BPI's 25 years of research, Most Loved Workplace® certification data, SPARK findings, and current workforce signals into practical analysis leaders can use.
The report format includes executive summaries, research-backed articles, company examples, methodology notes, and practical implications for retention, hiring, culture, leadership, and employee experience. New research and analysis is published on an ongoing editorial cadence at /workplace-report.